Literature DB >> 12138399

Novel targets of Akt, p21(Cipl/WAF1), and MDM2.

Binhua P Zhou1, Mien-Chie Hung.   

Abstract

The phosphatidylinositol-3-OH kinase (PI-3K)/Akt signaling pathway plays a critical role in tumorigenesis. This pathway is activated by the amplification or overexpression of HER2/neu, which occurs in 30% of human breast and ovarian cancers. The recent identification of a number of Akt substrates suggests that Akt can enhance cell proliferation and inhibit apoptosis. In this review we will discuss the theme of action of Akt in regulating the cellular localization of its substrates to control proliferation and apoptosis in light of two new identified Akt substrates, p21(Cip1/WAF1) and MDM2. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12138399     DOI: 10.1053/sonc.2002.34057

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  22 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

Review 2.  Nuclear and mitochondrial signalling Akts in cardiomyocytes.

Authors:  Shigeki Miyamoto; Marta Rubio; Mark A Sussman
Journal:  Cardiovasc Res       Date:  2009-03-11       Impact factor: 10.787

3.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

4.  A proteomic screen identified stress-induced chaperone proteins as targets of Akt phosphorylation in mesangial cells.

Authors:  Michelle T Barati; Madhavi J Rane; Jon B Klein; Kenneth R McLeish
Journal:  J Proteome Res       Date:  2006-07       Impact factor: 4.466

5.  Physiological regulation of Akt activity and stability.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

Review 6.  Mdm2 links genotoxic stress and metabolism to p53.

Authors:  Zhongfeng Wang; Baojie Li
Journal:  Protein Cell       Date:  2011-01-08       Impact factor: 14.870

7.  MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells.

Authors:  V Valero; H Wingate; S Chada; Y Liu; F Palalon; G Mills; K Keyomarsi; K K Hunt
Journal:  Cancer Gene Ther       Date:  2011-05-06       Impact factor: 5.987

Review 8.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

9.  Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.

Authors:  Hector Guillen-Ahlers; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

10.  Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.

Authors:  Rakesh Kumar; Stephen J Blakemore; Catherine E Ellis; Emanuel F Petricoin; Dexter Pratt; Michael Macoritto; Andrea L Matthews; Joseph J Loureiro; Keith Elliston
Journal:  BMC Genomics       Date:  2010-07-06       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.